|
 Roche said the European Commission has backed RoActemra as a
treatment for patients with severe, active and progressive
rheumatoid arthritis who have previously not been treated with
methotrexate.
About 40 million people worldwide are affected by rheumatoid
arthritis, a disease that causes joints to become chronically
inflamed and swollen.
RoActemra is already approved as a treatment for moderate-to-severe
rheumatoid arthritis in patients who have failed to respond
adequately or are intolerant to previous therapy.
(Reporting by Caroline Copley; Editing by Matt Driskill)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
[to top of second column] |
